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Abstract
A two-step approach is described to chemically camouflage the inert surface of model polystyrene nanospheres of 60 nm in diameter
against recognition by the body’s defenses. The first step was based on the strong protein adsorbing potency of polystyrene, and the second
step utilized the chemical reactivity of the adsorbed proteins for conjugation with cyanuric chloride-activated methoxypoly(ethylenegly-
col)5000, mPEG5000. Bovine serum albumin (BSA) and rat IgG were used as models of non-immune and immune proteins, respectively.
The maximum adsorbance values for both proteins were near expectation for a close-packed monolayer. Adsorption isotherms studies and
analysis of the hydrodynamic thickness of the adsorbed protein layer confirmed the close-packed side-on mode of adsorption for BSA and the
end-on mode of adsorption for IgG, respectively. Nucleophiles on the adsorbed proteins were then reacted with cyanuric chloride activated
mPEG5000. The average poly(ethyleneglycol) (PEG) content for a 60-nm nanospheres was found to be 13.7F 0.4 Amol PEG/Amol BSA and
3.6F 0.3 Amol PEG/Amol IgG. The interaction of both PEG-bearing nanospheres with the hydrophobic column material octyl-agarose
indicated surface heterogeneity among the nanospheres. Only nanospheres with the most hydrophilic phenotype (approximately 70% of the
total population) exhibited stealth properties after intravenous injection to rats. In contrast to the described approach, incubation of uncoated
nanospheres with preformed BSA-mPEG5000 conjugates failed to produce long circulating entities. For design of splenotropic particles
cyanuric chloride-activated mPEG5000 was conjugated to BSA-coated polystyrene beads of 225 nm in diameter. Despite their stealth
property to hepatic Kupffer cell recognition, these nanospheres were cleared by the splenic red pulp macrophages. D 2002 Elsevier Science
B.V. All rights reserved.
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1. Introduction
Poly(ethyleneglycol) (PEG) is a linear polyether diol
which exhibits a low degree of immunogenicity and anti-
genicity [1]. The PEG backbone is essentially chemically
inert, and the terminal primary hydroxyl groups are available
for derivatization. Usually, the hydroxyl groups are first
activated and then reacted with appropriate groups on the
chosen molecule [2]. For example, methoxypoly(ethylene-
glycol) (mPEG) was previously used to decrease immuno-
genicity and proteolysis of various macromolecules to
include albumin, interferon-g, interleukin-1, colony stimulat-
ing factor, and superoxide dismutase as well as to extend their
blood-circulation half-lives [2,3]. Today, this technology is
increasingly being exploited to camouflage antigenic deter-
minants of cells and tissues [4,5] and to engineer colloidal
carriers (e.g., liposomes, polymeric nanospheres) with pro-
longed circulation times [6]. Biomedical applications of long
circulating particles are discussed elsewhere [6].
Three different approaches have been described for the
design of polymeric nanospheres with surface exposed PEG
molecules [6]. These include incorporation of PEG during
nanoparticle production, covalent attachment of activated
PEG molecules to the surface reactive groups of preformed
particles, and physical adsorption of appropriate PEG deriv-
atives, such as poly(lactide-co-glycolide)-PEG, to nano-
spheres. The latter two approaches are the most common
but suffer from some limitations. One example is a nano-
particle with a poorly reactive surface. Another problem is
rapid desorption of physically adsorbed available PEG
derivatives, and hence the steric barrier, upon nanosphere
contact with the blood [6]; a process leading to immediate
nanoparticle capture by macrophages.
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To overcome these limitations, this manuscript introdu-
ces a simple approach for enriching the surface of relatively
inert polystyrene nanospheres with PEG. This approach
exploits the strong protein-adsorbing potency of nano-
spheres as well as the chemical reactivity of the adsorbed
proteins. Bovine serum albumin (BSA) and rat IgG were
used as models of non-immune and immune proteins,
respectively. These proteins adsorb strongly onto the surface
of nanoparticles at concentrations below and at the plateau
region of their respective adsorption isotherm [7]. Following
protein adsorption, cyanuric chloride-activated mPEG was
conjugated to tightly bound proteins, as both BSA and IgG
contain a large number of accessible reactive amino groups.
The surface-engineered nanospheres were fully character-
ized and their biodistribution was evaluated in rats follow-
ing intravenous injection.
2. Materials and methods
2.1. Preparation and characterization of activated reagents
and BSA-mPEG5000 conjugate
Activated mPEG550 was prepared following reaction of
mPEG550 (Sigma-Aldrich Company Ltd., Pool, UK) with
cyanuric chloride as described in detail elsewhere [1],
whereas cyanuric chloride-activated mPEG5000 was ob-
tained directly from Sigma-Aldrich and used as received.
Albumin-mPEG5000 was prepared and characterized ac-
cording to the procedures of Abuchowski et al. [1]. Briefly,
cyanuric chloride-activated mPEG5000 was added in 50-
fold molar excess to BSA in 0.1 M sodium tetraborate, pH
9.2. The mixture was incubated at 4 jC for 2 h. Following
the incubation, unattached PEG was removed by dialysis
(Mr cut-off 10,000) against 10 mM phosphate buffer, pH
7.4. Complete removal of free PEG molecules in dialysate
was monitored by the standard colorimetric assay of Nag et
al. [8] using ammonium ferrothiocyanate. As a control
experiment, free PEG molecules were also dialyzed under
the described condition to ensure their complete appearance
in the dialysate. Protein concentrations were determined by
the Biuret method [9]. Sheep anti-bovine albumin anti-
bodies (Serotec, Oxford, UK) reacted strongly with BSA
but not with BSA-mPEG5000 as determined by immuno-
diffusion studies, hence confirming that the antigenic sites
on BSA has been masked by the PEG chains. The covalent
attachment of activated mPEG5000 to BSA was also
assessed by SDS–polyacrylamide gel electrophoresis, using
a 7% separating gel and 5% stacking gel. In both cases,
conjugated proteins showed a diffused band of high molec-
ular weight with no discernible band corresponding to
unconjugated BSA. Finally, the quantity of PEGylation
was assessed by two different methods: a colorimetric me-
thod which is described in detail by Nag et al. [8] and is
based on partitioning of a chromophore present in ammo-
nium ferrothiocyanate reagent from an aqueous to a chloro-
form phase in the presence of PEG, and by estimating the
free amino groups available in the modified protein com-
pared to that in the native protein by 2,4,6-trinitrobenzene-
sulfonic acid (TNBS) method as described by Habeeb [10].
The validity of the colorimetric method of Nag et al. [8]
was confirmed since partition coefficients of free and
PEGylated BSA in a two-phase system of 100 mM saline
and chloroform were found to be comparable.
2.1.1. Treatment of polystyrene nanospheres
Polystyrene nanospheres (2.5% w/v) of 60 and 225 nm in
diameter, manufactured by Polysciences Inc. (USA), were
purchased from Park Scientific (Northampton, UK) and
surface labelled with Na[125I] (Amersham Pharmacia Bio-
tech, UK) as described previously [11]. Radiolabelled nano-
spheres with initial diameter of 60 nm without any surface
modification are referred to as Type A nanospheres. The
surface of Type A nanospheres was modified with either
BSA or IgG or BSA-mPEG5000 and their classification is
shown in Table 1. Initially, an adsorption isotherm of
proteins on polystyrene lattices was constructed as described
in detail elsewhere [7]. This was to ensure that the quantity
of adsorbed proteins was in the plateau region of their
respective isotherm prior to further modification with acti-
vated mPEGs. Briefly, protein/nanosphere suspensions were
prepared by adding 0.6 mg polystyrene particles with a total
surface area of 0.058 m2, to protein solutions ranging from 0
to 600 Ag/ml BSA or IgG in a total volume of 3.0 ml in
triplicate tubes. All tubes were gently shaken for 24 h at 24
jC. The suspensions were then centrifuged for 60 min at
150,000 g. Protein concentrations were determined by
BioRad assay for the resulting supernatants using a standard
curve run concurrent with the adsorption experiment. At 24
jC and at a pH of 7.2 and ionic strength of 0.015 M, BSA
showed a high affinity for the polystyrene at low concen-
trations. The isotherm was bimodal, after an initial sharp
increase, the isotherm leveled out around 0.95 mg/m2 and
then began to rise to a final concentration of 2.0 mg/m2. For
IgG, adsorption isotherm was determined under similar
conditions to that of BSA except that the ionic strength
was 0.005 M. Again, the isotherm was bimodal but with a
final plateau limit of 12.1 mg/m2. The protein coated
particles (at 2.0 and 12.1 mg/m2 for BSA and IgG, respec-
tively) were centrifuged for 60 min at 150,000 g. After
four washing steps and subsequent centrifugation, no more
Table 1




Type C Pre-incubated with BSA-mPEG5000
Type D BSA-coated then grafted with mPEG5000
Type E BSA-coated then grafted with mPEG550
Type F IgG-coated
Type G IgG-coated then grafted with mPEG5000
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protein was detected in the supernatant as assessed by the
BioRad protein assay solution. No nanospheres were lost in
supernatants as monitored by light scattering during centri-
fugation steps. The cleaned nanoparticles were finally
resuspended in either phosphate buffer or 0.1 M sodium
tetraborate at pH 9.2, and gently shaken for 24 h at 24 jC to
determine whether any protein could desorb from the nano-
spheres. These experiments demonstrated strong association
of adsorbed proteins with nanospheres; approximately 190
albumin and 585 IgG molecules per nanosphere, respec-
tively. These entities are referred to as Type B and Type F
nanoparticles, respectively. The above procedures were also
repeated to construct BSA-coated nanoparticles starting
from polystyrene beads of 225 nm in diameter; the final
constructs were estimated to contain approximately 2200
tightly bound BSA molecules.
Type C nanospheres were prepared by preincubation of
uncoated 60 nm nanoparticles (Type A) with BSA-
mPEG5000 at 24 jC for 24 h (0.6 mg polystyrene per
0.25 mg BSA). Types D and E nanoparticles were prepared
following conjugation of activated mPEG5000 and
mPEG550 to Type B nanospheres, respectively. Briefly,
Type B nanospheres were suspended in 0.1 M sodium
tetraborate at pH 9.2. Activated mPEG550 or mPEG5000
were added to the nanosphere suspensions in excess (in 50-
fold molar excess to adsorbed albumin) and incubated for 1
h at 4 jC. Unattached PEG molecules were removed by
centrifugation at 150,000 g for 60 min. Finally, nano-
sphere were suspended in 10 mM phosphate buffer, pH 7.2,
and washed three times to ensure the complete removal of
unattached PEGs. Removal of free PEG and the quantity of
adsorbed conjugated BSA-PEG were determined by the
colorimetric assay of Nag et al. [8]. The above procedures
were also repeated to covalently attach mPEG5000 to Type
F nanospheres and the resultant entities are referred to as
Type G nanoparticles. In a series of experiments, polystyr-
ene nanospheres of 225 nm in diameter (Polysciences) were
used to prepare Type D-like nanospheres according to the
above-described procedures.
2.2. Assessment of nanosphere size and electrophoretic
mobility
The hydrodynamic radius and the electrophoretic mobi-
lity of nanospheres were determined by photon correlation
spectroscopy (based on CONTIN analysis) and laser Dop-
pler electrophoresis, respectively, in 10 mM McIlvaine
buffer, pH 7.2, at 24 jC using a Zetasizer 3000 system
(Malvern Instruments, UK) as described previously [12]. In
some experiments, nanospheres were incubated in 25% v/v
rat serum for 30 min at 24 jC prior to analysis.
2.3. Hydrophobic interaction chromatography
The interaction of both Types A and D nanospheres with
hydrophobic column material was investigated by adsorp-
tion to and elution from octyl-agarose (Sigma-Aldrich); bed
volume = 23 ml, flow rate = 40 ml/h. In all experiments,
nanospheres (3.0 mg) were suspended in 10 mM phosphate
buffer (pH = 7.2) with 1.0 M sodium chloride to promote
interaction. The column was equilibrated with the same
buffer. Elution was made by decreasing the concentration of
sodium chloride and concurrently increasing the concen-
tration of Triton X-100 (from 0.0% to 0.1% v/v). No
aggregation of sample was observed before application onto
the column. The elution pattern was read by radioactivity.
For Type D nanoparticles, pooled fractions were concen-
trated by centrifugation for 60 min at 150,000 g and
washed twice with 10 mM phosphate buffer prior to
biodistribution studies.
2.4. Animal studies
Groups of three male Wistar rats, body weight 150F 10
g, were injected intravenously into a lateral tail vein with
various nanosphere preparations (0.6 mg polystyrene). At
the indicated time intervals, 20 Al blood samples were
removed from the second tail vein. Animals were killed 3
h post nanoparticle administration and selected organs were
removed and analysed for radioactivity content. To deter-
mine the amount of nanospheres in the blood, a total blood
volume per rat of 7.5% of body weight was assumed [11]. A
correction factor for the blood content in the liver was
determined as described earlier [11]. In some experiments,
animals were injected intravenously with 108 IgG-sensitized
sheep red blood cells (IgG-SRBC) 30 min prior to injection
of nanospheres. Details for preparation of IgG-SRBC are
given elsewhere [13].
2.5. Electron microscopy
The spleen was removed and sliced. The slices were
immersed in the fixative (2.5% glutaraldehyde in 0.08 M
cacodylate buffer, pH = 7.4) for 4 h. After initial aldehyde
fixation, the spleen samples were further processed as
described in detail elsewhere [14]. Briefly, slices were
washed in cacodylate buffer, dehydrated through graded
ethanol, and embedded in EMIX resin. Sections of 80 nm
were cut and stained with uranyl acetate followed by lead
citrate. The liver was fixed by the perfusion method and
processed as described in detail elsewhere [14]. Micro-
graphs were taken with a JOEL 1200 EX electron micro-
scope operated at 80 kV.
3. Results
3.1. Nanosphere characterization
The size and electrophoretic mobility values of nano-
spheres are given in Table 2. The average increase in the
hydrodynamic radius for a BSA-coated nanoparticle (Type
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B) is 3.0–3.5 nm. This increase in size together with the
results of the adsorption isotherm study correlates closely
with the side-on mode of BSA adsorption, since the approx-
imate ellipsoid dimensions of BSA is 3.8 3.8 14.0 nm
[7]. These suggestions are in accordance with the earlier
observations of Fair and Jamieson [7]. The results also indi-
cate an increase in particle size following coupling of activa-
ted mPEG5000 and mPEG550 to Type B nanospheres.
Similarly, incubation of nanospheres with BSA-mPEG5000
also increased their Z-average diameter. In contrast to a BSA-
conditioned polystyrene nanoparticle, the Stoke radius for an
IgG-coated nanoparticle (Type F) was in the order of 18–19
nm (Table 2), and increased by a further 2 nm after
PEGylation (Type G). Based on molecular hydrodynamic
dimensions of IgG (23.5 4.4 4.4 nm) [7] and a surface
concentration of 12.1 mg/m2, one calculates a close-packed
end-on monolayer mode of adsorption, which again is in
accordance with the earlier conclusion of Fair and Jamie-
son [7].
The addition of serum further increased the size of all
nanosphere regardless of their initial surface properties,
which could have been due to further surface adsorption
of serum proteins; particularly by a build up of complement
proteins at least with respect to Type F nanoparticles. The
polydispersity values in all particle size measurements were
less than 0.2.
Measurements of the electrophoretic mobility indicated
that the surface of nanospheres are different in buffer. How-
Table 2
Biophysical characteristics of control and protein-modified polystyrene nanospheres
Nanosphere Size (nm) Electrophoretic mobility (Am/s) (V/Cm) Average PEG content Amol PEG/
type
in buffer in serum in buffer in serum
Amol protein (BSA or IgG)
A 62.1F1.3 89.2F 2.1  5.018F 0.532  2.552F 0.021 –
B 69.2F 1.7 88.5F 3.1  2.917F 0.081  2.643F 0.049 –
C 76.6F 2.1 84.1F1.4  1.671F 0.041  2.159F 0.063 12.7F 0.9
D 77.8F 3.1 81.2F 1.9  0.810F 0.042  1.101F 0.031 6.9F 0.6
E 73.0F 1.4 81.6F 2.1  1.015F 0.062  1.979F 0.071 13.7F 0.4
F 99.8F 1.6 145.6F 2.2  2.234F 0.067  2.556F 0.027 –
G 103.4F 1.9 108.9F 2.1  1.002F 0.067  1.223F 0.071 3.6F 0.3
Fig. 1. Blood concentration of surface-modified polystyrene nanoparticles following intravenous injection into rats.
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ever, in the presence of serum the electrophoretic mobility
values for Types B, C, and F nanospheres approached that of
Type A. In contrast, mobility values of both Types D and G
nanospheres remained similar both in the absence and pres-
ence of serum and was significantly lower than Type A
nanospheres. Although the electrophoretic mobility of Type
E nanospheres was similar to those of Types D and G in a
bufferedmedium, the mobility was increased substantially by
incubation in serum.
Conjugation of mPEG5000 to free BSA molecules
resulted a value 12.7F 0.9 Amol PEG/Amol BSA, which
is in close agreement with the published data of Nag et al.
[8]. Table 2 also summarizes the surface PEG quantity of
nanospheres.
3.2. Biodistribution studies
The results in Fig. 1 compares the blood clearance of 60
nm polystyrene nanoparticles. Following intravenous injec-
tion, the majority of both Types A and B polystyrene
nanoparticles are cleared rapidly from the blood within the
first 15 min mainly by the liver and the spleen (Table 3).
Electron microscopic observations confirmed nanosphere
location in lysosomal structures of liver and spleen macro-
phages (sinusoidal Kupffer cells and the splenic red pulp
macrophages) (Fig. 2). Nanosphere uptake by hepatocytes
and liver endothelial cells was not observed, based on
electron microscopy and differential liver cell separation
studies (data not shown). To prolong the circulation time of
nanospheres, BSA-mPEG5000 conjugates were used first
for surface modification. Although electrophoretic mobility
studies indicated surface coverage with BSA-mPEG5000
(Type C nanospheres), such pre-treatments were ineffective
in keeping polystyrene nanospheres in the blood for pro-
longed periods. The clearance rate was slower than Types A
and B particles during the first hour, but at 3 h the blood
concentration of nanopsheres approached that of both Types
A and B (Fig. 1). Here, liver and spleen again participated in
nanosphere clearance from the blood (Table 3). In contrast
to the above entities, Type D nanospheres had a different
blood clearance profile. Here, 35–40% of the injected dose
of Type D nanospheres were cleared from the blood within
the first 15 min (Fig. 1). After this initial rapid clearance, the
remaining nanospheres removed poorly from the blood; at
the time of sacrifice, 45% of the initial dose was still
circulating (Fig. 1 and Table 3). Type E nanospheres were
slowly cleared from the blood with eventual localization to
the liver and the spleen.
To unravel the mechanisms responsible for the initial
disappearance of 35–40% of the injected dose of Type D
nanospheres, further experiments were designed. Hydro-
Table 3
Biodistribution of polystyrene nanoparticles evaluated at 3 h post
intravenous injection
Nanosphere % of injected dose
type
Liver Spleen Blood Recoverya
A 66.5F 1.7 1.1F 0.3 3.4F 0.7 76.3F 2.9
B 64.9F 0.5 0.7F 0.2 3.0F 1.0 74.3F 1.8
C 65.1F1.1 0.4F 0.1 5.1F1.3 74.4F 3.2
D 23.5F 1.9 1.8F 0.2 45.1F 0.7 72.1F 0.7
E 57.2F 3.1 1.1F 0.5 9.7F 2.3 72.6F 3.2
a Represents total radioactivity associated with liver, lung, spleen, blood,
tail (injection site), kidneys, tibia, and femoral bones.
Fig. 2. Electron micrograph of a lysosome from a rat periportal Kupffer cell. The micrograph demonstrates massive accumulation of Type B nanospheres in a
lysosome structure at 3 h post intravenous injection. Bar = 100 nm.
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phobic interaction chromatography indicated surface heter-
ogeneity among Type D nanoparticles. Passing a suspension
of Type D nanospheres in 1.0 M sodium chloride through a
hydrophobic column failed to retain the majority of nano-
particles (F1 peak) (Fig. 3a). When sodium chloride con-
centration was reduced to 0.5 M with a concomitant increase
in Triton X-100 concentration, a second peak (F2) was
eluted from the column. The biodistribution of nanospheres
collected under F1 peak was different to those collected
under F2 (Fig. 3b). Nanospheres of the F1 fraction exhibited
a prolonged circulation time with minimal localization to the
liver and the spleen. In contrast to Type D nanospheres,
there was no initial rapid clearance from the blood. Nano-
spheres of the F2 fraction were cleared gradually from the
blood with subsequent localization to the liver and the
spleen (Fig. 3b). The disappearance rate of the F2 nano-
Fig. 3. Hydrophobic interaction chromatography of Type D nanospheres on a column of octyl-agarose (a) and the blood concentration of eluted nanospheres
following intravenous injection to rats (b). In (a), the elution gradient is also shown (. . .), the two numbers above each gradient step represent the molarity of
sodium chloride (left) and % v/v of Triton X-100 (right). The elution profile of Type A nanoparticles is not shown but passing a suspension of such particles
through the column retarded nanospheres almost completely. When Triton X-100 was applied, nanospheres were eluted between fractions 84 and 92. The
above profile and tissue distribution outcome were reproducible and tested with three different preparations of Type D nanospheres.
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spheres from the blood was slower than that of Types A and
B nanospheres. An attempt was made to further PEGylate
the F2 fraction with activated mPEG5000 and the blood
longevity was improved following this step (41.1F 2.3% of
injected dose at 3 h).
Biodistribution of Type D nanospheres of 225 nm in
diameter was also investigated. In contrast to 60 nm Type D
nanoparticles, these larger nanospheres showed tendency for
splenic accumulation (Table 4). This was further evident at
24 h post intravenous injection were splenic sequestration
was in the order of 50% of the injected dose. Interestingly,
electron microscopic studies demonstrated accumulation of
these nanoparticles in lysosomal structures of red pulp
macrophages despite the initial presence of an effective
steric barrier on the surface of nanospheres (Fig. 4).
Type G nanospheres were constructed following PEGy-
lation of polystyrene nanoparticles that were pre-coated with
an immune protein (IgG). Prior to intravenous injection,
these nanospheres were passed through the hydrophobic
column as described for 60 nm Type D nanospheres again
with similar elution profile. The most hydrophilic fraction
(F1) was concentrated for intravenous injection. Such sur-
face modification procedures were also proved to be effec-
tive in keeping at least 40% of injected nanospheres in the
blood when compared to their corresponding control (Type
F) at the time of sacrifice (Table 5). Prior injection of IgG-
SRBC, which blocks or down regulate macrophage Fc
Table 4
Biodistribution of Type D nanospheresa of 225 nm in size following
intravenous injection
Analysis at % of injected dose
Liver Spleen Blood Recoveryb
3 h 16.8F 1.4 24.6F 3.1 36.8F 1.1 82.1F 3.9
24 h 20.8F 2.7 50.1F 5.7 0.9F 0.4 73.1F 2.8
Both uncoated and BSA-coated nanospheres (225 nm) were cleared rapidly
from the blood. In both cases, the hepatic and splenic uptake of nanospheres
were approximately 70% and 3% of the injected dose, respectively, when
measured 24 h post injection.
a Nanospheres were passed through a column of octyl-agarose and the
fraction collected in void volume (representing the most hydrophilic
population of nanospheres) was used for intravenous injection.
b See legend to Table 3.
Fig. 4. Electron micrographs of rat spleen red pulp macrophages 3 h (a) and 24 h (b) after intravenous injection of 225 nm Type D-like nanospheres. Bar = 1
Am. The micrographs shows accumulation of nanospheres in lysosomes.
Table 5
Biodistribution of Types F and G nanospheres evaluated at 3 h post
intravenous injection in control and animals predosed with IgG-sensitized
SRBC
Animals/ % of injected dose
nanospheres
Liver Spleen Blood Recoverya
Control/Type F 68.6F 0.8 2.5F 1.3 2.5F 2.1 77.2F 1.5
Control/Type G 24.6F 0.8 4.5F 1.3 45.2F 2.1 74.3F 1.6
IgG-SRBC
predosed/Type G
11.6F 1.2 2.3F 0.2 56.4F 3.4 73.3F 3.5
a See legend to Fig. 3.
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receptors, further increased blood longevity of Type G
nanospheres with a concomitant decrease in hepatic and
splenic localization (Table 5).
4. Discussion
Two different approaches were made to enrich the sur-
face of relatively inert polystyrene nanospheres with acti-
vated mPEG. The first approach was based on simple
incubation of nanoparticles with BSA-mPEG5000, a con-
jugate with an established long-circulating property [1].
Since BSA can adsorb strongly to hydrophobic surfaces,
the projected PEG5000 molecules are expected to afford a
high energy steric barrier to build-up of opsonic proteins
and hence poor macrophage recognition of the whole
construct [15]. This approach, however, proved unsuccess-
ful. The results of the eletrophoretic mobility studies of
nanoparticles in serum as well as their blood clearance
profile strongly indicate surface displacement of BSA-
mPEG by the blood proteins. It is likely that the steric
barrier arising from PEGylation prevents strong interaction
between hydrophobic microdomains of BSA and the par-
ticle surface, thus making the majority of adsorbed con-
jugates susceptible to displacement by blood proteins under
in vivo shear forces. Gradual shedding of the PEG portions
from particle surface is unlikely since the whole conjugate
in soluble form is known to exhibit a long circulating
property [1].
The second approach exploited the strong protein-
adsorbing potency of the polystyrene nanoparticles prior
to PEGylation step. Here, covalent attachment of activated
mPEG5000 to pre-adsorbed BSA, as an example of a non-
immune protein, and IgG, as an example of an immune
protein, proved effective in suppressing nanoparticle recog-
nition by the elements of the reticuloendothelial system and
further confirmed surface stability of the constructs within
the vasculature. These results are also comparable to blood
longevity of previously established poloxamine 908-coated
polystyrene nanoparticles [6,15,16]. Thus, this simple strat-
egy may be a useful approach for constructing long circu-
lating or stealth particles, particularly when dealing with an
inert surface. The validity of this approach for engineering
of long circulating liposomes should also be investigated as
both BSA and IgG are known to interact with the majority
of phospholipid bilayers [17]. It should also be emphasized
that the described approach is not restricted to BSA and
IgG; small hydrophobic peptides that contain free amino
groups can also be used as linkers for conjugation to
mPEG5000 since such peptides can coat the surface of
hydrophobic particles or even span through the lipid bilayer
of liposomes.
An interesting observation, however, was the rapid dis-
appearance of a significant fraction of Type D nanospheres
from the blood following intravenous injection. Two possi-
ble explanations could account for this behaviour. The first
possibility is that this could arise following immediate
displacement of some conjugate molecules by the blood
elements. Such partial displacements will decrease the steric
shielding at particular patches on the surface thus making
nanospheres prone to phagocytosis by macrophages in the
liver and the spleen. The second possibility can be attributed
to an inadequate coverage of the nanosphere surface with
mPEG-5000 molecules (e.g., a patchy surface) prior to
intravenous injection. Polymers are statistical mixtures.
The starting polymer which was used to prepare the cyanu-
ric chloride derivatives may have contained a range of low
molecular weight PEGs. Therefore, some areas on the sur-
face of particles may be enriched with low molecular weight
PEGs. These areas are expected to be more vulnerable to
surface opsonization processes. According to the manufac-
turer, the PEG derivatives used are monofunctional; one end
is capped by a methoxy group. Therefore, their reaction is
expected to give products free of cross-linking. However,
the theoretical possibility of some minor intramolecular and
intermolecular cross-linking on surface adsorbed proteins by
mPEG derivatives cannot be excluded. Nevertheless, hydro-
phobic interaction chromatography studies strongly indi-
cated surface heterogeneity among Type D nanospheres.
Of the two eluted fractions, only the F1 fraction was long
circulating; this further supports strong association of the
conjugate molecules with nanoparticle surface in vivo. On
the other hand, gradual removal of the F2 fraction nano-
spheres from the blood partially supports the second possi-
bility since further PEGylation of the F2 fraction with
activated mPEG5000 dramatically improved the blood lon-
gevity. Interestingly, this increased blood longevity failed to
approach to the level observed by the F1 fraction. One
plausible explanation is the loss of some surface adsorbed
proteins during the hydrophobic interaction chromatography
of Type D nanospheres. Unfortunately, no attempts were
made to detect and/or quantify protein loss during chroma-
tography.
PEGylation of IgG-coated particles (Type G) was also
effective in suppressing recognition by macrophage Fc
receptors as further confirmed by prior injection of IgG-
tagged SRBC. Unlike the F1 fraction of Type D nano-
psheres, a significant fraction of Type G nanoparticles
with the most hydrophilic phenotype was captured by the
elements of the reticuloendothelial system. Thus, despite
this chemical camouflage some surface adsorbed IgG
molecules can still initiate recognition by macrophage Fc
receptors. Although a patchy surface could lead to such in
vivo behavior, these observations may also indicate that
the attached PEG molecules are in a crowded arrange-
ment; a conformation which reduces polymer chain mobi-
lity and attenuates the effectiveness of the steric barrier
[6,18]. A close-packed end-on monolayer mode of adsorp-
tion for IgG, as compared to the side-on mode of BSA
adsorption, may further support this speculation. Never-
theless, these observations are interesting with regard to
possible targeting of Type G constructs (i.e., antibody-
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bearing) to accessible non-macrophage elements within
the vascular system.
Surface modification with mPEG550 failed to prolong
the circulation time of BSA-coated nanospheres (Type E).
Although more PEG550 molecules than PEG5000 are
associated per Amol of adsorbed BSA, the steric barrier
imposed by PEG550 must be inferior to that of PEG5000
presumably due to poor PEG chain mobility. Such surface
PEG conformations can explain susceptibility of Type E
nanospheres to phagocytosis. Indeed, the results of electro-
phoretic mobility of Type E particles in the presence of
serum further supports this suggestion since the value
approaches that of Type A nanospheres. These observations
are also similar to the earlier reported studies with liposomes
and nanoparticles bearing short surface PEG chains
[6,19,20].
Long circulating nanoparticles are cleared efficiently
from the blood by sinusoidal spleens providing that the
particles are non-deformable and their diameter exceeds the
size of interendothelial cell slits in the red pulp [6,14,16].
Therefore, rigid long circulating particles of 200 nm in
diameter or larger will be filtered at such cell slits and will
not reach the venous circulation. The current approach
further provided a simple method for engineering of
spleen-specific nanoparticles. Interestingly, filtered nano-
spheres were found intracellularly, in the lysosomal struc-
tures of red pulp macrophages, despite exhibiting an
efficient steric barrier to hepatic phagocytosis. The causes
for spleen macrophage recognition of such particles are not
clear, but these observations may prove to be important for
splenic delivery of antigenic peptides and proteins for
intravenous vaccination. Indeed, earlier observations have
confirmed that following internalization into phagosomes of
macrophages antigens coupled to polystyrene particles can
prime major histocompatibility complex class I-restricted
cytotoxic T lymphocyte responses [21,22].
Finally, it should be emphasized that prior to PEGylation
step, the surface of all nanospheres were enriched with
proteins at the plateau region of adsorption isotherm.
Previous studies of BSA and g-globulin adsorption on
polystyrene nanoparticles indicated that the adsorbed pro-
tein is in a form close to its native conformation through the
upper and lower plateau regimes of their respective isotherm
[7]. Thus, at low concentrations, adsorption proceeds by a
random uncorrelated irreversible mode, which may or may
not involve conformational mode. On the other hand, at
higher concentrations, a transition to a cooperative adsorp-
tion mode was suggested in which a close-packed mono-
layer is formed [7]. In light of these suggestions and
evidence for the presence of a population of Type D nano-
spheres with poor surface PEG coverage, it would be
interesting to examine the extent of PEGylation, PEG chain
mobility and the blood longevity of protein-coated poly-
styrene nanoparticles below the final plateau region of the
adsorption isotherm (e.g., disorganized surface structures
containing unoccupied areas as well as partly ordered
‘glassy’ structures).
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